This article is part of our CJC-1295 compound reference. All information is presented in a research context and does not constitute medical advice or recommendations for human use. Always conduct peptide research within appropriate institutional and regulatory frameworks.
Contrary to popular belief, CJC-1295 isn’t a single, well-defined pharmaceutical product sitting in a standardized vial on every supplier’s shelf. The name actually refers to two distinct research compounds — one with a Drug Affinity Complex (DAC) and one without — and the differences between them matter significantly for anyone sourcing material for legitimate research purposes. Understanding what you’re actually looking for, what the published literature covers, and how to separate credible suppliers from questionable ones is the foundation of responsible peptide research.
This guide synthesizes the available peer-reviewed evidence on CJC-1295, breaks down the relevant mechanism-of-action context, and offers a framework for evaluating research-grade suppliers in 2026.
What Is CJC-1295? A Mechanism Overview
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). In its original characterization, researchers found it to be a “GRF superagonist” — meaning it demonstrated a substantially longer half-life and more sustained receptor activation than native GHRH when tested in preclinical models PMID: 15849194.
The compound works by binding to GHRH receptors on somatotroph cells in the anterior pituitary gland. This interaction research suggests may stimulate pulsatile growth hormone (GH) secretion, which in turn can influence downstream insulin-like growth factor 1 (IGF-1) levels. It’s important to note that all of these observations exist within controlled research settings with institutional oversight.
DAC vs. Non-DAC: A Critical Distinction
When sourcing CJC-1295 for research, the first decision point is which version you’re looking at:
CJC-1295 with DAC (Drug Affinity Complex): This version attaches the peptide to an albumin-binding moiety, significantly extending its circulating half-life. Studies indicate this version may sustain GH and IGF-1 elevation for extended periods — on the order of days rather than hours PMID: 16332937.
CJC-1295 without DAC (often called Mod GRF 1-29): This modified version of GRF(1-29) eliminates certain amino acid substitutions to improve stability without the albumin-binding extension. It produces a shorter-acting pulse more closely mimicking natural GHRH release patterns. Research suggests this version supports a more physiological pulsatile secretion profile PMID: 18682518.
These aren’t interchangeable in research contexts. If you’re reviewing published protocols or designing experiments, the version matters — and a reputable supplier will clearly distinguish between them on their product pages. For a deeper head-to-head breakdown, see our CJC-1295 vs. Mod GRF 1-29 comparison.
What the Published Literature Shows
Before evaluating suppliers, it helps to understand what the research landscape actually looks like. The evidence base for CJC-1295 is narrow but informative:
Human Clinical Data
The most cited work comes from Teichman et al. (2006), a randomized, double-blind, placebo-controlled study in healthy adults. This research found that a single subcutaneous injection of CJC-1295 with DAC produced dose-dependent increases in mean GH and IGF-1 levels that persisted for over a week. The authors noted that the sustained release profile was consistent with the compound’s pharmacokinetic design, though they also observed that pulsatile GH secretion was preserved — a detail that distinguished it from continuous GH infusion approaches.
A follow-up investigation by Ionescu et al. (2008) specifically examined whether the continuous stimulation provided by CJC-1295 with DAC disrupted the natural pulsatile pattern of GH secretion. Their data indicated that pulsatile secretion persisted during continuous GHRH receptor activation, suggesting the somatotroph axis maintains some regulatory autonomy even under sustained stimulation.
Preclinical Foundation
The foundational pharmacology was established by Jetté et al. (2005), who identified CJC-1295 as a GHRH superagonist in rat models. This work demonstrated receptor activation dynamics and half-life characteristics that formed the basis for subsequent human study designs.
What’s Missing
It’s worth noting — with appropriate hedging — that the published clinical evidence remains limited. There are no large-scale, long-term efficacy trials. Most human data comes from small-sample, short-duration studies in healthy populations. This doesn’t invalidate the research; it simply means the evidence base is early-stage and anyone designing studies should account for this context.
Grouping Research Contexts by Mechanism
When evaluating CJC-1295’s relevance to a particular research question, it helps to organize the literature by mechanistic pathway rather than treating it as a monolithic compound:
1. GHRH Receptor Agonism Pathway This is the primary mechanism. CJC-1295 binds to and activates GHRH receptors, triggering intracellular signaling cascades (cAMP-dependent pathways) that promote GH gene transcription and hormone release. The bulk of the published literature falls here.
2. GH/IGF-1 Axis Modulation Downstream of GHRH receptor activation, studies have measured changes in circulating GH and IGF-1. These are secondary readouts — not direct effects of CJC-1295 itself but consequences of its primary mechanism. Evidence quality at this level is moderate, based on the clinical studies mentioned above.
3. Pulsatile Secretion Dynamics A subset of the literature specifically examines how sustained GHRH receptor activation interacts with the natural pulsatile rhythm of GH release. This represents a more nuanced mechanistic question, and the evidence — while interesting — comes from very small study populations.
4. Tissue-Level Downstream Effects Some research programs may be interested in what sustained IGF-1 elevation means for specific tissue types (muscle, bone, connective tissue). At this level, the evidence is largely inferential and extrapolated from broader IGF-1 literature rather than CJC-1295-specific studies. This is the weakest evidence tier.
Understanding which mechanistic layer your research question sits in will help you evaluate the relevance of available suppliers’ documentation, certificates of analysis (COAs), and supporting literature.
Evaluating Research-Grade Suppliers in 2026
The research peptide market in 2026 continues to operate in a regulatory landscape that rewards diligence. Here’s a framework for assessing suppliers:
Non-Negotiable Quality Markers
Third-Party Certificates of Analysis (COAs): Any supplier worth considering should provide batch-specific COAs from independent analytical laboratories — not in-house testing. Look for HPLC purity data (≥98% is the standard benchmark for research-grade peptides) and mass spectrometry confirmation of molecular identity. If a supplier only provides their own internal QC reports, that’s a significant gap.
Transparent Sourcing and Manufacturing Documentation: Legitimate research suppliers typically disclose whether their peptides are manufactured domestically or imported, and they provide documentation of GMP-adjacent (Good Manufacturing Practice) manufacturing standards. You don’t need a pharmaceutical-grade facility for research-grade material, but you need traceability.
Proper Research Disclaimers: Suppliers who explicitly market peptides for research use only — and enforce this through their purchasing terms — are signaling regulatory awareness. This is relevant because the legal status of research peptides has been a moving target, and suppliers who stay within appropriate boundaries tend to be more reliable overall.
Secondary Evaluation Criteria
Batch Consistency Data: Some suppliers publish historical purity data across multiple batches. Consistency over time is a meaningful quality signal.
Storage and Handling Documentation: Peptides are sensitive to temperature, light, and moisture. Suppliers who ship with cold packs, use appropriate lyophilization, and provide storage guidance demonstrate an understanding of compound integrity.
Customer Support and Technical Responsiveness: Can you reach someone who understands the compound? If you have questions about the difference between DAC and non-DAC versions, or about solubility protocols, a knowledgeable response is a good sign.
Red Flags to Watch For
Unrealistically low pricing. Peptide synthesis has real costs. If one supplier is dramatically cheaper than the field, there’s a reason — and it usually involves purity, identity, or fillers.
No COA, or COAs that look templated. If the same COA appears across multiple batches with identical numbers, that’s not a batch-specific analysis.
Health- or performance-oriented marketing language. Suppliers who market research peptides with fitness, anti-aging, or medical benefit claims are operating outside appropriate boundaries. This isn’t just a regulatory concern — it’s a signal that the business may be cutting corners elsewhere.
Vague or missing peptide identity information. You should be able to confirm amino acid sequence, molecular weight, salt form, and net peptide content from product documentation.
Our Research Supplier Evaluation Criteria
At CompoundGuide, we evaluate suppliers against a weighted framework:
-
Analytical documentation quality (30%): Third-party COAs, HPLC and MS data, batch-specific reporting.
-
Regulatory compliance signals (25%): Appropriate disclaimers, purchasing restrictions, awareness of current legal frameworks.
-
Product transparency (20%): Clear labeling of DAC vs. non-DAC, molecular specifications, storage requirements.
-
Reputation and track record (15%): How long the supplier has operated, peer researcher feedback, absence of documented quality incidents.
-
Operational reliability (10%): Shipping practices, customer service responsiveness, order accuracy.
No single supplier will score perfectly across every dimension. The goal is to identify suppliers whose documentation and practices allow you to make informed decisions about the material you’re using in your research.
The Regulatory Context
It’s worth briefly noting that the regulatory status of research peptides remains nuanced. CJC-1295 is not an FDA-approved pharmaceutical. It exists in the research-use-only category, and suppliers who operate responsibly maintain this distinction. The landscape has shifted several times in recent years, and staying informed about current legal frameworks is part of responsible research practice. Our 2026 peptide legality guide provides a more detailed treatment of this topic.
Frequently Asked Questions
What’s the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC includes a Drug Affinity Complex that extends the peptide’s half-life by binding it to circulating albumin. This results in sustained receptor activation over days.
Without DAC (often called Mod GRF 1-29), the compound has a shorter half-life and produces more transient, pulsatile GHRH receptor stimulation. Published research suggests the two versions produce meaningfully different pharmacokinetic profiles PMID: 18682518.
Is CJC-1295 legal to purchase for research?
The legal landscape for research peptides is nuanced and jurisdiction-dependent. CJC-1295 is not an FDA-approved drug and is generally sold under research-use-only designations. For a comprehensive breakdown of the current regulatory picture, see our 2026 peptide legality guide.
What purity level should I look for in research-grade CJC-1295?
Published analytical standards in the research peptide space typically reference ≥98% purity by HPLC analysis. However, purity is only one dimension — you also want mass spectrometry confirmation of molecular identity and documentation of net peptide content (as opposed to total content, which includes counterions and moisture).
How should research-grade CJC-1295 be stored?
Lyophilized peptides are generally stable when stored at -20°C or below, away from light and moisture. Reconstituted solutions have significantly shorter stability windows and should typically be used promptly or stored at 2–8°C for short periods. Always defer to the supplier’s specific storage documentation, as formulation details can affect stability.
Can I trust supplier-provided COAs?
Supplier-provided COAs are a starting point, not a guarantee. The key question is whether the COA comes from an independent third-party laboratory or from the supplier’s own QC department.
Third-party documentation with specific batch identifiers is significantly more reliable. Some researchers also choose to independently verify material through their own institutional analytical resources when the stakes of compound identity are high.
